New research shows USA is still most attractive country for biopharma investment

In a new study from Pugatch Consilium consultancy, the US and European economies continue to top the global charts in terms of attractiveness for biopharmaceutical investment.

Notwithstanding low costs and considerable potential, emerging markets still come in at the bottom. Canada is also found to be surprisingly low on the list compared to developed economies, mainly due to challenging intellectual property policies.

The study, Measuring the Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey (commissioned by trade group Pharmaceutical Research and Manufacturers of America: PhRMA), finds that economies with policy environments that support investment and innovation rank as the most attractive in the eyes of top level executives operating on the ground, while economies with weak biopharmaceutical policies are considered to be much less competitive.